{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T11:52:44Z","timestamp":1782906764175,"version":"3.54.5"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-05146-2","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T14:13:32Z","timestamp":1778249612000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hematologic malignancies burden in China compared with the United States 1990\u20132021 and projections to 2040"],"prefix":"10.1007","volume":"17","author":[{"given":"Wenshuai","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wentao","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixun","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"issue":"10440","key":"5146_CR1","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/S0140-6736(24)00757-8","volume":"403","author":"Global incidence","year":"2024","unstructured":"Global incidence. prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403(10440):2133\u201361.","journal-title":"Lancet"},{"issue":"3","key":"5146_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"Cancer J Clin"},{"issue":"7","key":"5146_CR3","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia. 2022;36(7):1703\u201319.","journal-title":"Leukemia"},{"issue":"7","key":"5146_CR4","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022;36(7):1720\u201348.","journal-title":"Leukemia"},{"key":"5146_CR5","unstructured":"Liu W, Liu J, Song Y et al. Burden of lymphoma in China, 2006\u20132016: an analysis of the Global Burden of Disease Study 2016. J Hematol Oncol 2019;12(1)."},{"key":"5146_CR6","doi-asserted-by":"crossref","unstructured":"Liu J, Liu W, Mi L et al. Incidence and mortality of multiple myeloma in China, 2006\u20132016: an analysis of the Global Burden of Disease Study 2016. J Hematol Oncol 2019;12(1).","DOI":"10.1186\/s13045-019-0807-5"},{"issue":"10440","key":"5146_CR7","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1016\/S0140-6736(24)00367-2","volume":"403","author":"Global burden of","year":"2024","unstructured":"Global burden of. 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403(10440):2100\u201332.","journal-title":"Lancet"},{"issue":"10062","key":"5146_CR8","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1016\/S0140-6736(16)30388-9","volume":"388","author":"GA Stevens","year":"2016","unstructured":"Stevens GA, Alkema L, Black RE, et al. Guidelines for Accurate and Transparent Health Estimates Reporting: the GATHER statement. Lancet. 2016;388(10062):e19\u201323.","journal-title":"Lancet"},{"issue":"10440","key":"5146_CR9","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1016\/S0140-6736(24)00933-4","volume":"403","author":"Global burden and strength of evidence for","year":"2024","unstructured":"Global burden and strength of evidence for. 88 risk factors in 204 countries and 811 subnational locations, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403(10440):2162\u2013203.","journal-title":"Lancet"},{"issue":"1","key":"5146_CR10","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1093\/ije\/dyaa196","volume":"50","author":"Z Liu","year":"2021","unstructured":"Liu Z, Xu K, Jiang Y, et al. Global trend of aetiology-based primary liver cancer incidence from 1990 to 2030: a modelling study. Int J Epidemiol. 2021;50(1):128\u201342.","journal-title":"Int J Epidemiol"},{"issue":"2","key":"5146_CR11","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/joim.13508","volume":"292","author":"T W\u00e4sterlid","year":"2022","unstructured":"W\u00e4sterlid T, Cavelier L, Haferlach C, et al. Application of precision medicine in clinical routine in haematology-Challenges and opportunities. J Intern Med. 2022;292(2):243\u201361.","journal-title":"J Intern Med"},{"key":"5146_CR12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1172\/jci.insight.124928","volume":"3","author":"KA Oetjen","year":"2018","unstructured":"Oetjen KA, Lindblad KE, Goswami M, et al. Human bone marrow assessment by single-cell RNA sequencing, mass cytometry, and flow cytometry. JCI Insight. 2018;3:23.","journal-title":"JCI Insight"},{"issue":"7","key":"5146_CR13","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.18632\/aging.204006","volume":"14","author":"W Liu","year":"2022","unstructured":"Liu W, Liu J, Song Y, et al. Burden of lymphoma in China, 1990\u20132019: an analysis of the global burden of diseases, injuries, and risk factors study 2019. Aging. 2022;14(7):3175\u201390.","journal-title":"Aging"},{"issue":"3","key":"5146_CR14","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.cll.2022.04.005","volume":"42","author":"CB Hergott","year":"2022","unstructured":"Hergott CB, Kim AS. Molecular Diagnostic Testing for Hematopoietic Neoplasms: Linking Pathogenic Drivers to Personalized Diagnosis. Clin Lab Med. 2022;42(3):325\u201347.","journal-title":"Clin Lab Med"},{"issue":"5","key":"5146_CR15","first-page":"Ecr15","volume":"89","author":"K Jentsch-Ullrich","year":"2004","unstructured":"Jentsch-Ullrich K, Pelz AF, Braun H, et al. Complete molecular remission in a patient with Philadelphia-chromosome positive acute myeloid leukemia after conventional therapy and imatinib. Haematologica. 2004;89(5):Ecr15.","journal-title":"Haematologica"},{"issue":"5","key":"5146_CR16","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937\u201351.","journal-title":"Blood"},{"issue":"20","key":"5146_CR17","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375\u201390.","journal-title":"Blood"},{"key":"5146_CR18","doi-asserted-by":"crossref","unstructured":"Inaba H, Pui CH. Advances in the Diagnosis and Treatment of Pediatric Acute Lymphoblastic Leukemia. J Clin Med 2021;10(9).","DOI":"10.3390\/jcm10091926"},{"issue":"11","key":"5146_CR19","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1038\/s41375-023-02048-y","volume":"37","author":"NCP Cross","year":"2023","unstructured":"Cross NCP, Ernst T, Branford S, et al. European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia. Leukemia. 2023;37(11):2150\u201367.","journal-title":"Leukemia"},{"issue":"5","key":"5146_CR20","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/ajh.27625","volume":"100","author":"S Shimony","year":"2025","unstructured":"Shimony S, Stahl M, Stone RM, Acute Myeloid L. 2025 Update on Diagnosis, Risk-Stratification, and Management. Am J Hematol. 2025;100(5):860\u201391.","journal-title":"Am J Hematol"},{"issue":"7","key":"5146_CR21","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med. 2020;383(7):617\u201329.","journal-title":"N Engl J Med"},{"issue":"3","key":"5146_CR22","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1400376","volume":"371","author":"JC Byrd","year":"2014","unstructured":"Byrd JC, Brown JR, O\u2019Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213\u201323.","journal-title":"N Engl J Med"},{"issue":"10","key":"5146_CR23","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, et al. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Engl J Med. 2017;376(10):917\u201327.","journal-title":"N Engl J Med"},{"issue":"9","key":"5146_CR24","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/S1470-2045(14)70311-0","volume":"15","author":"A Younes","year":"2014","unstructured":"Younes A, Thieblemont C, Morschhauser F, et al. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. Lancet Oncol. 2014;15(9):1019\u201326.","journal-title":"Lancet Oncol"},{"issue":"5","key":"5146_CR25","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1200\/JCO.2012.42.7211","volume":"31","author":"L Fayad","year":"2013","unstructured":"Fayad L, Offner F, Smith MR, et al. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I\/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. J Clin Oncol. 2013;31(5):573\u201383.","journal-title":"J Clin Oncol"},{"issue":"23","key":"5146_CR26","doi-asserted-by":"publisher","first-page":"2834","DOI":"10.1097\/CM9.0000000000002600","volume":"136","author":"J Liu","year":"2023","unstructured":"Liu J, Liu W, Mi L, et al. Burden of multiple myeloma in China: an analysis of the Global Burden of Disease, Injuries, and Risk Factors Study 2019. Chin Med J (Engl). 2023;136(23):2834\u20138.","journal-title":"Chin Med J (Engl)"},{"issue":"9","key":"5146_CR27","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","volume":"30","author":"S Kumar","year":"2012","unstructured":"Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30(9):989\u201395.","journal-title":"J Clin Oncol"},{"issue":"26","key":"5146_CR28","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863\u20139.","journal-title":"J Clin Oncol"},{"issue":"1","key":"5146_CR29","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s13045-019-0807-5","volume":"12","author":"J Liu","year":"2019","unstructured":"Liu J, Liu W, Mi L, et al. Incidence and mortality of multiple myeloma in China, 2006\u20132016: an analysis of the Global Burden of Disease Study 2016. J Hematol Oncol. 2019;12(1):136.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"5146_CR30","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1038\/s41375-023-01852-w","volume":"37","author":"K Hemminki","year":"2023","unstructured":"Hemminki K, Hemminki J, F\u00f6rsti A, et al. Survival in hematological malignancies in the Nordic countries through a half century with correlation to treatment. Leukemia. 2023;37(4):854\u201363.","journal-title":"Leukemia"},{"issue":"17","key":"5146_CR31","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1200\/JCO.18.02151","volume":"37","author":"J Nie","year":"2019","unstructured":"Nie J, Wang C, Liu Y, et al. Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed\/Refractory Classical Hodgkin Lymphoma. J Clin Oncol. 2019;37(17):1479\u201389.","journal-title":"J Clin Oncol"},{"issue":"19 Suppl","key":"5146_CR32","first-page":"s5453","volume":"52","author":"PM Banks","year":"1992","unstructured":"Banks PM. Changes in diagnosis of non-Hodgkin\u2019s lymphomas over time. Cancer Res. 1992;52(19 Suppl):s5453\u20135.","journal-title":"Cancer Res"},{"issue":"10","key":"5146_CR33","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1002\/1097-0142(19901115)66:10<2196::AID-CNCR2820661026>3.0.CO;2-R","volume":"66","author":"SL Glaser","year":"1990","unstructured":"Glaser SL, Swartz WG. Time trends in Hodgkin\u2019s disease incidence. The role of diagnostic accuracy. Cancer. 1990;66(10):2196\u2013204.","journal-title":"Cancer"},{"key":"5146_CR34","unstructured":"Guidelines for the diagnosis and management of multiple myeloma in China. (2024 revision). Zhonghua Nei Ke Za Zhi 2024;63(12):1186\u20131195."},{"issue":"5","key":"5146_CR35","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/bjh.16238","volume":"188","author":"HSH Chan","year":"2020","unstructured":"Chan HSH, Milne RJ. Impact of age, sex, ethnicity, socio-economic deprivation and novel pharmaceuticals on the overall survival of patients with multiple myeloma in New Zealand. Br J Haematol. 2020;188(5):692\u2013700.","journal-title":"Br J Haematol"},{"issue":"1","key":"5146_CR36","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/ajh.26744","volume":"98","author":"C Radkiewicz","year":"2023","unstructured":"Radkiewicz C, Bruchfeld JB, Weibull CE, et al. Sex differences in lymphoma incidence and mortality by subtype: A population-based study. Am J Hematol. 2023;98(1):23\u201330.","journal-title":"Am J Hematol"},{"issue":"6","key":"5146_CR37","doi-asserted-by":"publisher","first-page":"6711","DOI":"10.1002\/cam4.5461","volume":"12","author":"N Stabellini","year":"2023","unstructured":"Stabellini N, Tomlinson B, Cullen J, et al. Sex differences in adults with acute myeloid leukemia and the impact of sex on overall survival. Cancer Med. 2023;12(6):6711\u201321.","journal-title":"Cancer Med"},{"key":"5146_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2020.01.018","volume":"130","author":"MA Karalexi","year":"2020","unstructured":"Karalexi MA, Dessypris N, Ma X, et al. Age-, sex- and disease subtype-related foetal growth differentials in childhood acute myeloid leukaemia risk: A Childhood Leukemia International Consortium analysis. Eur J Cancer. 2020;130:1\u201311.","journal-title":"Eur J Cancer"},{"key":"5146_CR39","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12874-015-0057-3","volume":"15","author":"PC Lambert","year":"2015","unstructured":"Lambert PC, Dickman PW, Rutherford MJ. Comparison of different approaches to estimating age standardized net survival. BMC Med Res Methodol. 2015;15:64.","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"5146_CR40","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1186\/s12889-025-21890-6","volume":"25","author":"Q Pan","year":"2025","unstructured":"Pan Q, Zhang W, Chen X, et al. A study of trends in body morphology, overweight, and obesity in Chinese adults aged 40\u201359 years. BMC Public Health. 2025;25(1):833.","journal-title":"BMC Public Health"},{"issue":"22","key":"5146_CR41","doi-asserted-by":"publisher","first-page":"751","DOI":"10.46234\/ccdcw2025.124","volume":"7","author":"X Zeng","year":"2025","unstructured":"Zeng X, Liu S, Liu Y, et al. Smoking Prevalence in Urban and Rural Areas - China, 2024. China CDC Wkly. 2025;7(22):751\u20139.","journal-title":"China CDC Wkly"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-05146-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05146-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05146-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T11:37:16Z","timestamp":1782905836000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-05146-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5146"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-05146-2","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"assertion":[{"value":"15 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"961"}}